<DOC>
	<DOC>NCT02716766</DOC>
	<brief_summary>The purpose of this study is to determine if sorafenib, capecitabine and oxaliplatin (SECOX) regimen is more effective than sorafenib alone in the treatment of advanced liver cancer.</brief_summary>
	<brief_title>Study of SECOX Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (HCC)</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Advanced or metastatic hepatocellular carcinoma (HCC) not suitable for surgery or various locoregional therapies. Diagnosis of HCC confirmed either by cytohistological confirmation or by noninvasive criteria according to the European Association for Study of Liver disease (EASL) criteria. ChildPugh A or B7 cirrhosis. Eastern CoOperative Group (ECOG) performance status ≤ 2. Life expectancy of ≥ 12 weeks. Adequate organ function (blood transfusion or use of biologic response modifiers is not permitted). Measurable disease with at least one lesion, which is at least 1 cm in one dimension on computed tomography (CT) or magnetic resonance imaging (MRI). Able and willing to meet all protocolrequired treatments, investigations and visits. Signed written informed consent form. Prior systemic therapy for advanced HCC. Central nervous system (CNS) metastasis. History of liver transplantation. Peripheral sensory neuropathy with functional impairment before the first cycle of treatment. History of cardiac disease. Uncontrolled hypertension. Women who are pregnant or breastfeeding, or women of childbearing potential who are unable or unwilling to practice a highly effective means of contraception. Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of study results.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Sorafenib</keyword>
	<keyword>Drug Therapy</keyword>
</DOC>